|Mr. Brett Anthony Mitchell||Exec. Chairman||289.76k||N/A||1973|
|Mr. Roby Reuven Zomer||Co-Founder, CEO, MD & Exec. Director||406.41k||N/A||N/A|
|Mr. Nativ Segev||Co-Founder, Head of Bus. Strategy & Exec. Director||393.54k||N/A||N/A|
|Ms. Rachel Jelleff Kerr||Company Sec.||N/A||N/A||N/A|
|Hugh Winters||Chief Exec. Officer of MGC Derma||N/A||N/A||N/A|
MGC Pharmaceuticals Limited, a biopharmaceutical company, produces and supplies phytocannabinoid derived medicines in Australia, Slovenia, and other European countries. The company provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; CannEpil and CannEKids for refractory epilepsy; and TopiCann for anti-inflammatory topical treatment. It also offers MGC CBD for anti-inflammatory, antioxidant, neuroprotector, anxiolytic, analgesic, antidepressant, anti-psychotic, and anti-tumoral agent; and MGC THC for nausea and vomiting associated with cancer medicines, as well as enhance the appetite of people with AIDS. MGC Pharmaceuticals Limited has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, The Hebrew University of Jerusalem, University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.
MGC Pharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.